Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPMAIA, Carlos R.STELLA, Steffan F.WAGNER, FlaviaPIANCA, Thiago G.KRIEGER, Fernanda V.CRUZ, Luciane N.POLANCZYK, Guilherme V.ROHDE, Luis A.POLANCZYK, Carisi A.2016-07-182016-07-182016REVISTA BRASILEIRA DE PSIQUIATRIA, v.38, n.1, p.30-38, 20161516-4446https://observatorio.fm.usp.br/handle/OPI/14370Objective: To perform a cost-utility analysis on the treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate immediate-release (MPH-1R) in children and adolescents from Brazil. Method: A Markov model was constructed to compare MPH-1R vs. no treatment. A 24 -week naturalistic study was conducted to collect transition probabilities and utility data. Effectiveness was expressed as quality -adjusted life -years (QALY), and costs reported in 2014 international dollars (1$). The perspective was the Brazilian Unified Health System as payer, and the time horizon was 6 years. Results: Of 171 patients, 73 provided information at baseline, and 56 at week 24. Considering the MPH-1R monthly cost of 1$ 38, the incremental cost-effectiveness ratio (ICER) of treatment was 1$ 9,103/QALY for children and 1$ 11,883/QALY for adolescents. In two-way sensitivity analysis, considering one Gross National Product per capita (1$ 11,530) as willingness-to-pay,a cost of no-treatment lower than 1$ 45/month would render MPH-IR a cost-saving strategy. Discussion: MPH-1R treatment of children and adolescents is cost-effective for ADHD patients from the Brazilian public health system perspective. Both patients and the healthcare system might benefit from such a strategy.engopenAccessAttention deficit hyperactivity disordercost-utility analysismethylphenidateattention-deficit/hyperactivity disorderdeficit hyperactivity disorderquality-of-lifeeconomic-evaluationhealthchildhoodsurvivorsschedulevaliditysystemarticleCopyright ASSOC BRASILEIRA PSIQUIATRIA10.1590/1516-4446-2014-1516Psychiatry1809-452X